FDA Granted Fast Track Status to Type 1 Diabetes Drug
The immunotherapy candidate SAB-142 aims to treat adults with new-onset Stage 3 type 1 diabetes.
Updated on Oct. 13, 2026 in Diabetes
Live Poll
Do you trust that pharmaceutical companies are prioritizing speed for patients with serious unmet medical needs?
The U.S. Food and Drug Administration has granted Fast Track designation to the immunotherapy candidate SAB-142 for the treatment of Stage 3 type 1 diabetes. This regulatory status is intended to expedite the development and review process for the drug, which is currently being studied in two clinical trials.
Why it matters
This designation recognizes the potential of SAB-142 to address a significant unmet medical need for patients recently diagnosed with type 1 diabetes. By facilitating more frequent communication with the FDA, the status may help accelerate the timeline for bringing this potential new treatment to the public.
SAB-142 is being evaluated in the ongoing Phase 2b SAFEGUARD trial, which focuses on patients within 100 days of a Stage 3 type 1 diabetes diagnosis. A second study, the PRISE-hATG trial, is examining the therapy in a broader population diagnosed up to two years prior.
The players
U.S. Food and Drug Administration
The federal agency responsible for protecting public health by ensuring the safety and efficacy of medical products and pharmaceuticals.
SAB Biotherapeutics
A clinical-stage biopharmaceutical company focused on developing immunotherapies for autoimmune and infectious diseases using transchromosomic cattle.
The details
SAB-142 is an immunotherapy candidate developed by SAB Biotherapeutics using genetic engineering in transchromosomic cattle to produce human immunoglobulin G. The drug is designed to provide targeted immunological support for individuals with new-onset Stage 3 type 1 diabetes. Fast Track designation is a regulatory mechanism that allows for more frequent meetings with the FDA and eligibility for priority review to speed up the development of treatments for serious conditions.
Timeline
October 13, 2026: The FDA granted Fast Track designation to SAB-142.
Q4 2026: Expected completion of enrollment for the SAFEGUARD study.
2H 2027: Anticipated release of topline data from the SAFEGUARD study.
Health Landscape
The use of Fast Track designation aligns with the current trend of utilizing regulatory pathways to accelerate innovative immunotherapies for type 1 diabetes. This development sits alongside ongoing research into disease-modifying treatments that seek to manage immune responses in patients with recent diagnoses.
This development reflects an ongoing shift in clinical research toward earlier intervention strategies for newly diagnosed type 1 diabetes patients. It is worth discussing current and emerging treatment options for newly diagnosed conditions with your endocrinologist to stay informed about potential research opportunities.
The takeaway
The FDA has fast-tracked an immunotherapy candidate that could change how Stage 3 type 1 diabetes is managed. If you or a loved one have been recently diagnosed, consider speaking with a physician about the latest research trials and whether participation in clinical studies is an appropriate path.
What happens next
Enrollment for the SAFEGUARD clinical study is expected to conclude in Q4 2026, with topline data anticipated to be released in the second half of 2027.
Further reading
For more information on the current landscape of care, visit Diabetes.
Live Poll
Do you trust that pharmaceutical companies are prioritizing speed for patients with serious unmet medical needs?
